# Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

> **NCT05025423** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 7 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Venetoclax Oral Tablet [Venclexta]

## Key facts

- **NCT ID:** NCT05025423
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-21
- **Primary completion:** 2025-05-14
- **Final completion:** 2025-05-14
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study sponsor withdrew funding early, forcing this study to stop all activity and close pre-maturely.
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025423, "Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05025423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*